CS-2164 is under clinical development by Shenzhen Chipscreen Biosciences and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CS-2164’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CS-2164 overview

CS-2164 (Chiauranib) is under development for the treatment of small-cell lung cancer, fallopian tube cancer, relapsed and refractory non-Hodgkin lymphoma, epithelial ovarian cancer, liver cancer, ovarian cancer, colorectal cancer, kidney cancer, gastric cancer, lung cancer including non-small cell lung cancer, gastrointestinal stromal tumor, small-cell lung cancer, liver cancer, non-small cell lung carcinoma, colorectal cancer, neuroendocrine tumors, hepatocellular carcinoma, ovarian cancer, breast cancer, peritoneal carcinoma, soft tissue sarcoma, triple-negative breast cancer (TNBC), HER2- Breast Cancer and other solid tumors and soft tissue sarcomas including liposarcoma, leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, fibrosarcoma Sarcoma, clear cell sarcoma, angiosarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor, undifferentiated sarcoma, Ewing's sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberanoma, myofibroblastic sarcoma, malignant solitary fibroma, radiotherapy Posterior sarcoma, acinar soft tissue sarcoma, well-differentiated/dedifferentiated liposarcoma. It is administered orally as a capsule. The drug candidate is a small molecule. It acts by targeting aurora B, PDGFR, c-kit, vascular and endothelial growth factor receptor. The drug candidate is developed using chemical genomics-based discovery platform. It was also under development for the treatment of diffuse large B-cell lymphoma and peripheral T-cell lymphoma, renal cell carcinoma.

Shenzhen Chipscreen Biosciences overview

Shenzhen Chipscreen Biosciences (Chipscreen) operates as a biotechnology company that discovers and develops proprietary small molecule therapeutics for pharmaceutical and drug development. The company’s pipeline products include Chidamide, Chiglitazar, Chiauranib, CS3158, CS510, CS410, CS2164 and MeiGanLe. Its Chidamide chidamide is a novel subtype selective HDAC inhibitor functioning as an epigenetic modulator for the treatment of various haematological and solid cancers. Chipscreen offers protocol design, clinical research and monitoring, and data analysis and management services. The company provides clinical and preclinical stage programs in various therapeutic areas. Chipscreen is headquartered in Shenzhen, China.

For a complete picture of CS-2164’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.